News

Codexis has commercialised its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. Codexis said

The Phase 3 clinical trial is designed as a multi-center, randomised, crossover, outpatient study of the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of every 12-hour DR Cysteamine

XmAb5574, which will be renamed MOR208, is a humanised anti-CD19 monoclonal antibody for the treatment of B-cell malignancies. The contract provides MorphoSys with an exclusive worldwide license to

According to the study the addition of Dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were treated

According to OraSure Technologies, OraQuick is a test strip and does not require an instrument for diagnosis. It takes about 20 minutes to obtain results from the test

NCX 434 is a nitric oxide (NO)-donating new molecular entity (NME) and a potential preclinical candidate in diabetic macular edema (DME). NicOx’s new preclinical study demonstrated that NCX

Mymetics’ scientists, in collaboration with the Molecular Virology department of the University of Groningen, found that two consecutive injections of the vaccine at a two-week interval successfully protected

Under the terms of the agreement, Gilead will acquire CGI for up to $120m, the majority as an upfront payment and the remaining based on clinical development progress,

Linagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, is a once-daily oral treatment in type 2 diabetes. Boehringer Ingelheim said that the results of the trial were presented at the